- Conditions
- Virus Diseases
- Interventions
- Danirixin 15 mg FBE, Danirixin 50 mg FBE, Placebo, Oseltamivir 75 mg
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 5
- States / cities
- Stamford, Connecticut • Council Bluffs, Iowa • Natchitoches, Louisiana + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 961–984
of 13,291
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma
- Interventions
- Bendamustine Hydrochloride, Carboplatin, Rituximab, Etoposide, Laboratory Biomarker Analysis
- Drug · Biological · Other
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Hookworm Infection
- Interventions
- Na-ASP-2/Alhydrogel Hookworm Vaccine, Saline placebo
- Biological
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2006
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Avian Influenza
- Interventions
- aH5N1c, Placebo
- Biological
- Lead sponsor
- Seqirus
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,196 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 26
- States / cities
- Huntsville, Alabama • Chandler, Arizona • Tempe, Arizona + 20 more
- Conditions
- Tobacco Use Disorder
- Interventions
- Varenicline, Contingency Management, Counseling
- Drug · Behavioral
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 181 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 3
- States / cities
- Charleston, South Carolina • Florence, South Carolina • Pickens, South Carolina
- Conditions
- Malaria
- Interventions
- MAM01 1.5 mg/kg, Placebo, MAM01 5 mg/kg, MAM01 10 mg/kg, MAM01 40 mg/kg, MAM01 450 mg, Control, MAM01 600 mg, MAM01 900 mg
- Biological · Other
- Lead sponsor
- Gates Medical Research Institute
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Memory Loss (Excluding Dementia), Healthy Lifestyle, Risk Reduction Behavior
- Interventions
- My Healthy Brain 1, My Healthy Brain 2
- Behavioral
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Liver Diseases, Hepatic Impairment
- Interventions
- PF-07923568
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 3
- States / cities
- Tustin, California • Orlando, Florida • Tampa, Florida
- Conditions
- Sexual Dysfunction, Sexuality and Reproductive Issues, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- ArginMax, Placebo
- Dietary Supplement
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 186 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 25
- States / cities
- Newark, Delaware • Miami Beach, Florida • Augusta, Georgia + 21 more
- Conditions
- Epilepsy (Treatment Refractory)
- Interventions
- Seizure risk forecast, Control seizure risk forecast
- Other
- Lead sponsor
- Insel Gruppe AG, University Hospital Bern
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Adverse Childhood Experience, Endothelial Function (FMD), Endothelial Injury, Mitochondrial Function, Oxidative Stress, Psychosocial Influence on Cardiovascular Disease
- Interventions
- Mitoquinone mesylate (MitoQ), Placebo
- Dietary Supplement
- Lead sponsor
- University of Iowa
- Other
- Eligibility
- 18 Years to 29 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Hidradenitis Suppurativa
- Interventions
- Sonelokimab, Placebo
- Drug
- Lead sponsor
- MoonLake Immunotherapeutics AG
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 422 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 36
- States / cities
- Los Angeles, California • Northridge, California • Sacramento, California + 31 more
- Conditions
- Obesity Type 2 Diabetes Mellitus, Obese Adults, Type 2 Diabetes Mellitus
- Interventions
- Not listed
- Lead sponsor
- Profil Institut für Stoffwechselforschung GmbH
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2028
- U.S. locations
- 1
- States / cities
- Webster, Texas
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Metastatic Extrahepatic Bile Duct Cancer, Recurrent Adult Primary Liver Cancer, Recurrent Extrahepatic Bile Duct Cancer, Stage D Adult Primary Liver Cancer (BCLC), Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- PET scan, CT Scan, hepatic artery embolization
- Procedure
- Lead sponsor
- Fox Chase Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Male Breast Cancer, Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Adult Brain Tumor, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Colon Cancer, Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Recurrent Hypopharyngeal Cancer, Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Recurrent Laryngeal Cancer, Recurrent Lip and Oral Cavity Cancer, Recurrent Lymphoepithelioma of the Nasopharynx, Recurrent Lymphoepithelioma of the Oropharynx, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Recurrent Mucoepidermoid Carcinoma of the Oral Cavity, Recurrent Nasopharyngeal Cancer, Recurrent Non-small Cell Lung Cancer, Recurrent Oropharyngeal Cancer, Recurrent Pancreatic Cancer, Recurrent Paranasal Sinus and Nasal Cavity Cancer, Recurrent Rectal Cancer, Recurrent Renal Cell Cancer, Recurrent Salivary Gland Cancer, Stage IIIA Breast Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Breast Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Pancreatic Cancer, Stage IV Renal Cell Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVA Salivary Gland Cancer, Stage IVB Colon Cancer, Stage IVB Salivary Gland Cancer, Stage IVC Salivary Gland Cancer, Tongue Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- 18F-fludeoxyglucose (18F-FDG), 18F-FPPRGD2
- Drug
- Lead sponsor
- Sanjiv Sam Gambhir
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Asthma
- Interventions
- Multi-Component Technology Based Intervention
- Behavioral
- Lead sponsor
- Wayne State University
- Other
- Eligibility
- 18 Years to 29 Years
- Enrollment
- 192 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Kidney Cancer, Leukemia, Liver Cancer, Lung Cancer, Pancreatic Cancer, Tobacco Use Disorder
- Interventions
- bupropion hydrochloride, placebo
- Drug · Other
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2015
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Major Depressive Disorder
- Interventions
- LY2216684, Placebo, SSRI
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,416 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 22
- States / cities
- Irvine, California • La Habra, California • Redlands, California + 19 more
- Conditions
- Lung Cancer Stage III, Lung Cancer Stage IV
- Interventions
- Self System Therapy for Older Adults with Advanced Lung Cancer (SST-LC) Resilience
- Behavioral
- Lead sponsor
- Duke University
- Other
- Eligibility
- 65 Years to 100 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Pediatric Solid Tumor, Germ Cell Tumor, Retinoblastoma, Hepatoblastoma, Wilms Tumor, Rhabdoid Tumor, Carcinoma, Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, Synovial Sarcoma, Clear Cell Sarcoma, Malignant Peripheral Nerve Sheath Tumors, Desmoplastic Small Round Cell Tumor, Soft Tissue Sarcoma, Neuroblastoma
- Interventions
- second generation 4-1BBζ EGFR806-EGFRt, second generation 4-1BBζ EGFR806-EGFRt and a second generation 4 1BBζ CD19-Her2tG
- Biological
- Lead sponsor
- Seattle Children's Hospital
- Other
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2040
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Coronary Artery Disease
- Interventions
- YMI024, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 9
- States / cities
- Fairhope, Alabama • Foley, Alabama • Los Angeles, California + 6 more
- Conditions
- Atrial Fibrillation (AF)
- Interventions
- REGN7508, REGN9933, Apixaban
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 43
- States / cities
- Dothan, Alabama • Fairhope, Alabama • Covina, California + 36 more
- Conditions
- HIV-1-infection, HIV Infections, HIV I Infection
- Interventions
- CAB + RPV
- Drug
- Lead sponsor
- Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Anaplastic Large Cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Mantle Cell Lymphoma
- Interventions
- belinostat, rituximab, yttrium Y 90 ibritumomab tiuxetan
- Drug · Biological · Radiation
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Tucson, Arizona